Non-castrate metastatic prostate cancer: Have the treatment options changed?

Seminars in Oncology

Volumn 40, Issue 3, 2013, Pages 337-346

  Palmbos, Phillip L ^a   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ARN 509; BICALUTAMIDE; CABOZANTINIB; CIXUTUMUMAB; CYPROTERONE ACETATE; DEGARELIX; DIETHYLSTILBESTROL; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; GALETERONE; ISOSORBIDE; LEUPRORELIN; NILUTAMIDE; ORTERONEL; PLACEBO; PREDNISONE; SIPULEUCEL T; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; BONE REMODELING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; META ANALYSIS (TOPIC); MONOTHERAPY; NEGATIVE FEEDBACK; NON CASTRATE METASTATIC PROSTATE CANCER; NONHUMAN; ORCHIECTOMY; OSTEOCLAST ACTIVITY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR GROWTH;

ADENOCARCINOMA; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84879447404     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.007     Document Type: Article

References (62)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 2012 10 29
2. W.P. Harris, P.S. Mostaghel, and B. Nelson Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion Nat Clin Pract Urol 6 2 2009 76 85
3. J.M. Ruch, and M.H. Hussain Evolving therapeutic paradigms for advanced prostate cancer Oncology (Williston Park) 25 6 2011 496 504
4. N. Sharifi, and R.J. Auchus Steroid biosynthesis and prostate cancer Steroids 77 7 2012 719 726
5. R. Venkitaraman, K. Thomas, and R.A. Huddart Efficacy of low-dose dexamethasone in castration-refractory prostate cancer BJU Int 101 4 2008 440 443
6. C. Huggins, and C.V. Hodges Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate J Urol 168 1 2002 9 12
7. D.P. Byar Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate Cancer 32 5 1973 1126 1130
8. R.L. Cox, and E.D. Crawford Estrogens in the treatment of prostate cancer J Urol 154 6 1995 1991 1998
9. Leuprolide versus diethylstilbestrol for metastatic prostate cancer The Leuprolide Study Group N Engl J Med 311 20 1984 1281 1286
10. H. Van Poppel, and L. Klotz Gonadotropin-releasing hormone: an update review of the antagonists versus agonists Int J Urol 19 7 2012 594 601
11. L. Klotz, L. Boccon-Gibod, and N.D. Shore The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 11 2008 1531 1538
12. B. Tombal, K. Miller, and L. Boccon-Gibod Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics Eur Urol 57 5 2010 836 842
13. H. Akaza Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness Cancer Sci 102 1 2011 51 56
14. D.J. Samson, J. Seidenfeld, and B. Schmitt Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 95 2 2002 361 376
15. A. Koupparis, R.G. Casey, R. Casey, M. Robinson, and M.E. Gleave Novel targeted agents on the horizon for castration-resistant prostate cancer Future Oncol 6 12 2010 1883 1895
16. C.J. Ryan, and D.J. Tindall Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically J Clin Oncol 29 27 2011 3651 3658
17. J.T. Isaacs, and D.S. Coffey Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma Cancer Res 41 12 Pt 1 1981 5070 5075
18. N. Bruchovsky, P.S. Rennie, A.J. Coldman, S.L. Goldenberg, M. To, and D. Lawson Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res 50 8 1990 2275 2282
19. P.J. Saylor, and M.R. Smith Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer J Natl Compr Canc Netw 8 2 2010 211 223
20. F.E.C. Calais da Silva, A.V. Bono, and P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group European Urology 55 6 2009 1269 1277
21. N. Mottet, J. Van Damme, S. Loulidi, C. Russel, A. Leitenberger, and J.M. Wolff Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial BJU Int 110 9 2012 1262 1269
22. A.J. Salonen, K. Taari, M. Ala-Opas, J. Viitanen, S. Lundstedt, and T.L.J. Tammela The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer J Urol 187 6 2012 2074 2081
23. J.F. Langenhuijsen, D. Badhauser, B. Schaaf, L.A.L.M. Kiemeney, J.A. Witjes, and P.F.A. Mulders Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer Urol Oncol 2011 [Epub ahead of print]
24. M. Hussain, C.M. Tangen, and H.S. Celestia Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial J Clin Oncol 30 suppl 2012 abstr 4
25. C.K. Osborne, B. Blumenstein, and E.D. Crawford Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study J Clin Oncol 8 10 1990 1675 1682
26. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study J Clin Oncol 17 8 1999 2506 2513
27. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 2004 1513 1520
28. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 2004 1502 1512
29. T.B. Dorff, C.M. Tangen, and E.D. Crawford Cooperative Group Trials - Southwest Oncology Group (SWOG) innovations in advanced prostate cancer Ther Adv Med Oncol 1 2 2009 69 77
30. E.G. Bluemn, and P.S. Nelson The androgen/androgen receptor axis in prostate cancer Curr Opin Oncol 24 3 2012 251 257
31. Y. Rehman, and J.E. Rosenberg Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer Drug Des Devel Ther 6 2012 13 18
32. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 21 2011 1995 2005
33. C. Ryan, M. Smith, and J. DeBono Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol 30 suppl 2012 abstr LBA4518
34. C. Massard, and K. Fizazi Targeting continued androgen receptor signaling in prostate cancer Clin Cancer Res 17 12 2011 3876 3883
35. M. Yamaoka, T. Hara, and T. Hitaka Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys J Steroid Biochem Mol Biol 129 3-5 2012 115 128
36. H.I. Scher, F. Saad, and M.E. Taplin Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study J Clin Oncol 30 suppl 2012 abstr LBA1
37. T. Vasaitis, A. Belosay, and A. Schayowitz Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer Mol Cancer Ther 7 8 2008 2348 2357
38. N.J. Clegg, J. Wongvipat, and J.D. Joseph ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res 72 6 2012 1494 1503
39. S. Kojima, M. Inahara, H. Suzuki, T. Ichikawa, and Y. Furuya Implications of insulin-like growth factor-I for prostate cancer therapies Int J Urol 16 2 2009 161 167
40. S.R. Plymate, K. Haugk, and I. Coleman An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer Clin Cancer Res 13 21 2007 6429 6439
41. G.R. MacVicar, B. Somer, F.A. Greco, K. Brill, and L. Leopold An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC) J Clin Oncol 26 suppl 2008 abstr 16043
42. M.N. Stein, I. Khan, and M. Hussain Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC) J Clin Oncol 29 suppl 7 2011 abstr 137
43. L.V. July, M. Akbari, T. Zellweger, E.C. Jones, S.L. Goldenberg, and M.E. Gleave Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy Prostate 50 3 2002 179 188
44. K.N. Chi, S.J. Hotte, and E.Y. Yu Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 27 2010 4247 4254
45. W.K. Kelly, S. Halabi, and M. Carducci Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J Clin Oncol 30 13 2012 1534 1540
46. G. Sonpavde, P.O. Periman, and D. Bernold Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann Oncol 21 2 2010 319 324
47. M. Dror Michaelson, M.M. Regan, and W.K. Oh Phase II study of sunitinib in men with advanced prostate cancer Ann Oncol 20 5 2009 913 920
48. D.C. Smith Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease J Clin Oncol 29 suppl 7 2011 abstr 127
49. P.A. Humphrey, X. Zhu, and R. Zarnegar Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma Am J Pathol 147 2 1995 386 396
50. M. Verras, J. Lee, H. Xue, T.H. Li, Y. Wang, and Z. Sun The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression Cancer Res 67 3 2007 967 975
51. M.R. Smith, F. Saad, and R. Coleman Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 9810 2012 39 46
52. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 9768 2011 813 822
53. F. Saad, D.M. Gleason, and R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 11 2004 879 882
54. D.P. Dearnaley, M.R. Sydes, and M.D. Mason A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial) J Natl Cancer Inst 95 17 2003 1300 1311
55. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 19 2006 3089 3094
56. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 5 2010 411 422
57. C.S. Higano, P.F. Schellhammer, and E.J. Small Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 16 2009 3670 3679
58. E.J. Small, N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 6 2007 1810 1815
59. M.K. Tollefson, R.J. Karnes, and R.H. Thompson A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer Genitourinary Cancers Symposium 2010 Abstract 168. March 5-7, 2010, San Francisco, USA
60. C. Tangen, M. Hussain, and C. Higano Improved overall survival trends of men with newly diagnosed M1 prostate cancer. a SWOG phase III trial experience (S8494, S8894 & S9346) J Urol 188 4 2012 1164 1169
61. M. Hussain, C.M. Tangen, and C. Higano Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group trial 9346 (INT-0162) J Clin Oncol 24 24 2006 3984 3990
62. P.D. Grivas, D.M. Robins, and M. Hussain Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer Crit Rev Oncol Hematol 2012